No Data
No Data
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): has accumulated repurchased 0.4479% of the company's shares.
Nucien pharmaceutical co., ltd. (688189.SH) announced that as of August 31, 2024, the company has repurchased a total of 1,228,955 shares of the company through the Shanghai Stock Exchange trading system through centralized bidding trading, accounting for 0.4479% of the total share capital of the company of 274,400,000 shares. The highest price for repurchase transactions was 9.24 yuan per share, the lowest price was 5.45 yuan per share, and the total amount paid was RMB 7,997,384.37 (excluding stamp duty, transaction fees, and other transaction costs).
Nanxin Pharmaceutical 2024 Semi-Annual Report
Summary of Nanxin Pharmaceutical\'s 2024 Semi-Annual Report
hunan nucien pharmaceutical co., ltd. (688189.SH): a net loss of 4.45 million yuan in the first half of the year.
hunan nucien pharmaceutical co., ltd. (688189.SH) announced that its revenue in the first half of 2024 was approximately 0.191 billion yuan, a year-on-year decrease of 62.86%; the net income attributable to shareholders of the listed company was a loss of approximately 4.45 million yuan; and the basic earnings per share was a loss of 0.0162 yuan.
Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH): The company did not repurchase shares in June.
On June 2024, Hunan Nucien Pharmaceutical Co., Ltd. (688189.SH) announced that it did not repurchase any shares. As of June 30, 2024, the company has accumulated repurchased 1,228,955 shares of the company through Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.4479% of the total share capital of 274,400,000 shares, with a highest repurchase price of 9.24 yuan per share and a lowest repurchase price of 5.45 yuan per share. The total amount paid for this repurchase is RMB 7,997,384.37 (excluding transaction fees such as stamp duty and trading commission).
Nucien Pharma Completes Phase 2 Trials for Influenza Drug
No Data
No Data